Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 772-781

  Münch, Daniela ^a   Engels, Ina ^a,b   Müller, Anna ^a   Reder Christ, Katrin ^a   Falkenstein Paul, Hildegard ^a   Bierbaum, Gabriele ^a   Grein, Fabian ^a   Bendas, Gerd ^a   Sahl, Hans Georg ^a   Schneider, Tanja ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID; ORITAVANCIN; PEPTIDOGLYCAN; PEPTIDYLTRANSFERASE; VANCOMYCIN; ANTIINFECTIVE AGENT; GLYCOPEPTIDE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL WALL; BINDING AFFINITY; BINDING SITE; HYDROGEN BOND; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; CHEMISTRY; DRUG EFFECTS; ENTEROCOCCUS FAECIUM; MICROBIAL SENSITIVITY TEST; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECIUM; GLYCOPEPTIDES; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS;

EID: 84921752352     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02663-14     Document Type: Article

References (71)

1. Arthur M, Courvalin P. 1993. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 37:1563-1571.http://dx.doi.org/10.1128/AAC.37.8.1563.
2. McCormick MH, Stark WM, Pittenger GE, Pittenger RC, McGuire JM. 1956. Vancomycin, a new antibiotic. Chemical and biological properties. Antibiot Annu 1955-1956:606-611.
3. Courvalin P. 1990. Resistance of enterococci to glycopeptides. Antimicrob Agents Chemother 34:2291-2296. http://dx.doi.org/10.1128/AAC .34.12.2291.
4. Leclercq R, Derlot E, Duval J, Courvalin P. 1988. Plasmid mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 319:157-161. http://dx.doi.org/10.1056/NEJM198807213190307.
5. Uttley AHC, Collins CH, Naidoo J, George RC. 1988. Vancomycinresistant enterococci. Lancet i:57-58.
6. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, National Healthcare Safety Network Team, Participating National Healthcare Safety Network Facilities. 2008. Antimicrobialresistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at Centers for Disease Control and Prevention 2006-2007. Infect Control Hosp Epidemiol. 29:996-1011. http://dx.doi.org/10.1086/591861.
7. Livermore DM. 2012. Fourteen years in resistance. Int J Antimicrob Agents 39:283-294. http://dx.doi.org/10.1016/j.ijantimicag.2011.12.012.
8. Nicas TI, Allen NE. 1994. Resistance and mode of action, p 219-241. In Nagarajan R (ed), Glycopeptide antibiotics. Marcel Dekker, New York, NY.
9. Reynolds PE. 1989. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 8:943-950. http: //dx.doi.org/10.1007/BF01967563.
10. Schneider T, Sahl HG. 2010. An oldie but a goodie-cell wall biosynthesis as antibiotic target pathway. Int J Med Microbiol 300:161-169. http: //dx.doi.org/10.1016/j.ijmm.2009.10.005.
11. Perkins HR, Nieto M. 1974. The chemical basis for the action of the vancomycin group of antibiotics. Ann N Y Acad Sci 235:348-363. http: //dx.doi.org/10.1111/j.1749-6632.1974.tb43276.x.
12. Bugg TDH, Wright GD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT. 1991. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins vanH and vanA. Biochemistry 30:10408-10415. http://dx.doi.org/10.1021/bi00107a007.
13. Walsh CT, Fisher SL, Park IS, Prahalad M, Wu Z. 1996. Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem Biol 3:21-28. http://dx.doi.org/10.1016/S1074-5521(96)90079-4.
14. Reynolds PE, Snaith HA, Maguire AJ, Dutka-Malen S, Courvalin P.1994. Analysis of peptidoglycan precursors in vancomycin-resistant Enterococcus gallinarum BM4174. Biochem J 301:5-8.
15. Malabarba A, Nicas TI, Thompson RC. 1997. Structural modifications of glycopeptide antibiotics. Med Res Rev 17:69-137. http://dx.doi.org/10 .1002/(SICI)1098-1128(199701)17:1<69::AID-MED3>3.0.CO;2-R.
16. Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. 2004. Glycopeptide antibiotics: from conventional molecules to new derivatives. Drugs 64:913-936. http://dx.doi.org/10.2165/00003495-200464090-00001.
17. Pace JL, Yang G. 2006. Glycopeptides: update on an old successful antibiotic class. Biochem Pharmacol 71:968-980. http://dx.doi.org/10.1016/j .bcp.2005.12.005.
18. Van Bambeke F, Mingeot-Leclercq MP, Struelens MJ, Tulkens PM. 2008. The bacterial envelope as a target for novel anti-MRSA antibiotics. Trends Pharmacol Sci 29:124-134. http://dx.doi.org/10.1016/j.tips.2007 .12.004.
19. Leung SF, Tirado-Rives J, Jorgensen WL. 2009. Vancomycin analogs: seeking improved binding of D-Ala-D-Ala and D-Ala-D-Lac peptides by side-chain and backbone modifications. Bioorg Med Chem 17:5874-5886. http://dx.doi.org/10.1016/j.bmc.2009.07.006.
20. Li TL, Liu YC, Lyu SY. 2012. Combining biocatalysis and chemoselective chemistries for glycopeptide antibiotics modification. Curr Opin Chem Biol 16:170-178. http://dx.doi.org/10.1016/j.cbpa.2012.01.017.
21. Allen NE. 2010. From vancomycin to oritavancin: the discovery and development of a novel lipoglycopeptide antibiotic. Antinfect Agents Med Chem 9:23-47. http://dx.doi.org/10.2174/187152110790886745.
22. Arthur M, Depardieu F, Reynolds P, Courvalin P. 1999. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob Agents Chemother 43:1875-1880.
23. Cooper RD, Snyder NJ, Zweifel MJ. 1996. Reductive alkylation of glycopeptides antibiotics: synthesis and antibacterial activity. J Antibiot (Tokyo) 49:575-581. http://dx.doi.org/10.7164/antibiotics.49.575.
24. Lu W, Oberthur M, Leimkuhler C, Tao J, Kahne D, Walsh CT. 2004. Characterization of a regiospecific epivancosaminyl transferase GtfA and enzymatic reconstitution of the antibiotic chloroeremomycin. Proc Natl Acad Sci U S A 101:4390-4395. http://dx.doi.org/10.1073/pnas .0400277101.
25. Belley A, McKay GA, Arhin FF, Sarmiento I, Beaulieu S, Fadhil I, Parr TR, Jr, Moeck G. 2010. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing. Antimicrob Agents Chemother 54:5369-5371. http://dx.doi.org/10.1128/AAC.00760-10.
26. McKay GA, Beaulieu S, Arhin FF, Beaulieu S, Sarmiento I, Parr TR, Jr, Moeck G. 2009. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J Antimicrob Chemother 63:1191-1199. http://dx.doi.org/10.1093 /jac/dkp126.
27. Saravolatz LD, Pawlak J, Johnson JB. 2010. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA). Int J Antimicrob Agents 36:69-72. http://dx.doi.org/10.1016/j .ijantimicag.2010.02.023.
28. Arhin FF, Drahi DC, Pillar CM, Parr TR, Jr, Moeck G, Sahm DF. 2009.Comparative in vitro activity profile of oritavancin against recent grampositive clinical isolates. Antimicrob Agents Chemother 53:4762-4771. http://dx.doi.org/10.1128/AAC.00952-09.
29. Morrow T. 2014. One-shot staph treatment offers many advantages. Manag Care 23:55-56.
30. Domenech O, Dufrene YF, Van Bambeke F, Tukens PM, Mingeot-Leclercq MP. 2010. Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus. Biochim Biophys Acta 1798:1876-1885. http://dx.doi.org/10.1016/j.bba mem.2010.06.011.
31. Nicolaou KC, Hughes R, Cho SY, Winssinger N, Labischinski H, Endermann R. 2001. Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: targetaccelerated combinatorial synthesis. Chem Eur J 7:3824-3843. http://dx .doi.org/10.1002/1521-3765(20010903)7:17<3824::AID-CHEM3824>3. 0.CO;2-1.
32. Mackay JP, Gerhard U, Beauregard DA, Westwell MS, Searle MS, Williams DH. 1994. Glycopeptide antibiotic activity and the possible role of dimerization: a model for biological signalling. J Am Chem Soc 116: 4581-4590. http://dx.doi.org/10.1021/ja00090a006.
33. Gerhard U, Mackay JP, Maplestone RA, Williams DH. 1993. The role of the sugar and chlorine substituents in the dimerization of vancomycin antibiotics. J Am Chem Soc 115:232-237. http://dx.doi.org/10.1021 /ja00054a033.
34. Beauregard DA, Williams DH, Gwynn MN, Knowles DJ. 1995. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob Agents Chemother 39:781-778. http://dx.doi.org/10.1128/AAC.39.3.781.
35. Ge M, Chen Z, Onishi HR, Kohler J, Silver LL, Kerns R, Fukuzawa S, Thompson C, Kahne D. 1999. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 284:507-511. http://dx.doi.org/10.1126/science.284.5413.507.
36. Kim SJ, Cegelski L, Stueber D, Singh M, Dietrich E, Tanaka KS, Parr TR, Jr, Far AR, Schaefer J. 2008. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J Mol Biol 377: 281-293. http://dx.doi.org/10.1016/j.jmb.2008.01.031.
37. Veiga P, Piquet S, Maisons A, Furlan S, Courtin P, Chapot-Chartier MP, Kulakauskas S. 2006. Identification of an essential gene responsible for D-Asp incorporation in the Lactococcus lactis peptidoglycan crossbridge. Mol Microbiol 62:1713-1724. http://dx.doi.org/10.1111/j.1365 -2958.2006.05474.x.
38. Bellais S, Arthur M, Dubost L, Hugonnet JE, Gutmann L, van Heijenoort J, Legrand R, Brouard JP, Rice L, Mainardi JL. 2006. Aslfm, the D-aspartate ligase responsible for the addition of D-aspartic acid onto the peptidoglycan precursor of Enterococcus faecium. J Biol Chem 281:11586-11594. http://dx.doi.org/10.1074/jbc.M600114200.
39. Kim SJ, Cegelski L, Preobrazhenskaya M, Schaefer J. 2006. Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotationalecho double resonance. Biochemistry 45:5235-5250. http://dx.doi.org/10 .1021/bi052660s.
40. Patti GJ, Kim SJ, Yu TY, Dietrich E, Tanaka KS, Parr TR, Jr, Far AR, Schaefer J. 2009. Vancomycin and oritavancin have different modes of action in Enterococcus faecium. J Mol Biol 392:1178-1191. http://dx.doi .org/10.1016/j.jmb.2009.06.064.
41. Severin A, Tabei K, Tenover F, Chung M, Clarke N, Tomasz A. 2004. High level oxacillin and vancomycin resistance and altered cell wall composition in Staphylococcus aureus carrying the staphylococcal mecA and the enterococcal vanA gene complex. J Biol Chem 279:3398-3407. http: //dx.doi.org/10.1074/jbc.M309593200.
42. Allen NE, LeTourneau DL, Hobbs JN, Jr, Thompson RC. 2002. Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies. Antimicrob Agents Chemother 46:2344-2348. http://dx .doi.org/10.1128/AAC.46.8.2344-2348.2002.
43. Brötz H, Bierbaum G, Leopold K, Reynolds PE, Sahl HG. 1998. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob Agents Chemother 42:154-160.
44. Schneider T, Gries K, Josten M, Wiedemann I, Pelzer S, Labischinski H, Sahl HG. 2009. The lipopeptide antibiotic friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob Agents Chemother 53:1610-1618. http://dx.doi.org/10.1128 /AAC.01040-08.
45. Schneider T, Senn MM, Berger-Bächi B, Tossi A, Sahl HG, Wiedemann I. 2004. In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of Staphylococcus aureus. Mol Microbiol 53:675-685. http://dx.doi.org/10.1111/j.1365-2958.2004.04149.x.
46. Münch D, Roemer T, Lee SH, Engeser M, Sahl HG, Schneider T. 2012. Identification and in vitro analysis of the GatD/MurT enzyme-complex catalyzing lipid II amidation in Staphylococcus aureus . PLoS Pathog 8:e1002509. http://dx.doi.org/10.1371/journal.ppat.1002509.
47. Umbreit JN, Strominger JL. 1972. Isolation of the lipid intermediate in peptidoglycan biosynthesis from Escherichia coli. J Bacteriol 112:1306-1309.
48. Christ K, Rüttinger HH, Höpfner M, Rothe U, Bendas G. 2005. The detection of UV-induced membrane damages by a combination of two biosensor techniques. Photochem Photobiol 81:1417-1423. http://dx.doi .org/10.1562/2005-04-19-RA-493.
49. Christ K, Wiedemann I, Bakowsky U, Sahl HG, Bendas G. 2007. The role of lipid II in membrane binding of and pore formation by nisin analyzed by two combined biosensor techniques. Biochim Biophys Acta 1768: 694-704. http://dx.doi.org/10.1016/j.bbamem.2006.12.003.
50. Simonis D, Christ K, Alban S, Bendas G. 2007. Affinity and kinetics of different heparins binding to P- and L-selectin. Semin Thromb Hemost 33:534-539. http://dx.doi.org/10.1055/s-2007-982085.
51. Brötz H, Josten M, Wiedemann I, Schneider U, Götz F, Bierbaum G, Sahl HG. 1998. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol 30:317-327. http://dx.doi.org/10.1046/j.1365-2958.1998.01065.x.
52. Rohrer S, Ehlert K, Tschierske M, Labischinski H, Berger-Bächi B. 1999. The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation. Proc Natl Acad Sci U S A 96:9351-9356. http://dx.doi.org/10.1073/pnas.96.16.9351.
53. Allen NE, Hobbs JN, Nicas TI. 1996. Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother 40:2356-2362.
54. Belley A, Harris R, Beveridge T, Parr T, Jr, Moeck G. 2009. Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. Antimicrob Agents Chemother 53:800-804. http://dx.doi.org/10.1128/AAC.00603-08.
55. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K. 1998. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother 42:315-320. http://dx.doi.org/10.1093/jac/42.3 .315.
56. Ammam F, Meziane-Cherif D, Mengin-Lecreulx D, Blanot D, Patin D, Boneca IG, Courvalin P, Lambert T, Candela T. 2013. The functional vanGCd cluster of Clostridium difficile does not confer vancomycin resistance. Mol Microbiol 89:612-625. http://dx.doi.org/10.1111/mmi.12299.
57. Hugonnet JE, Haddache N, Veckerlé C, Dubost L, Marie A, Shikura N, Mainardi JL, Rice LB, Arthur M. 2014. Peptidoglycan cross-linking in glycopeptide-resistant actinomycetales. Antimicrob Agents Chemother 58:1749-1756. http://dx.doi.org/10.1128/AAC.02329-13.
58. Cegelski L, Steuber D, Mehta AK, Kulp DW, Axelsen PH, Schaefer J. 2006. Conformational and quantitative characterization of oritavancinpeptidoglycan complexes in whole cells of Staphylococcus aureus by in vivo 13Cand 15Nlabeling. J Mol Biol 357:1253-1262. http://dx.doi.org/10.1016 /j.jmb.2006.01.040.
59. Boyle-Vavra S, Labischinski H, Ebert Ehlert CCK, Daum RS. 2001. A spectrum of changes occurs in peptidoglycan composition of glycopep-tide-intermediate clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother 45:280-287. http://dx.doi.org/10.1128/AAC.45.1.280 -287.2001.
60. Schäberle TF, Vollmer W, Frasch HJ, Hüttel S, Kulik A, Röttgen M, Von Thaler AK, Wohlleben W, Stegmann E. 2011. Self-resistance and cell wall composition in the glycopeptide producer Amycolatopsis balhimycina. Antimicrob Agents Chemother 55:4283-4289. http://dx.doi.org /10.1128/AAC.01372-10.
61. Cremniter J, Mainardi JL, Josseaume N, Quincampoix JC, Dubost L, Hugonnet JE, Marie A, Gutmann L, Rice LB, Arthur M. 2006. Novel mechanisms of resistance to glycopeptide antibiotics in Enterococcus faecium. J Biol Chem 281:32254-32262. http://dx.doi.org/10.1074/jbc .M606920200.
62. Nieto M, Perkins HR. 1971. Modification of the acyl-D-alanyl-D-alanine terminus affecting complex-formation with vancomycin. Biochem J 123: 789-803.
63. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23:99-139. http://dx.doi.org/10.1128/CMR .00042-09.
64. Severin A, Wu SW, Tabei K, Tomasz A. 2004. Penicillin-binding protein 2 is essential for expression of high-level vancomycin resistance and cell wall synthesis in vancomycin-resistant Staphylococcus aureus carrying the vanA gene complex. Antimicrob Agents Chemother 48:4566-4573. http: //dx.doi.org/10.1128/AAC.48.12.4566-4573.2004.
65. Strandén AM, Ehlert K, Labischinski H, Berger-Bächi B. 1997. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J Bacteriol 179: 9-16.
66. Koyama N, Tokura Y, Münch D, Sahl HG, Schneider T, Shibagaki Y, Ikeda H, Tomoda H. 2012. The nonantibiotic small molecule cyslabdan enhances the potency of β-lactams against MRSA by inhibiting pentaglycine interpeptide bridge synthesis. PLoS One 7:e48981. http://dx.doi.org /10.1371/journal.pone.0048981.
67. Hong HJ, Hill MH, Hill LM, Buttner MJ. 2005. The role of the novel Fem protein VanK in vancomycin resistance in Streptomyces coelicolor. J Biol Chem 280:13055-13061. http://dx.doi.org/10.1074/jbc.M413801200.
68. Bouhss A, Josseaume N, Severin Tabei AK, Hugonnet JE, Shlaes D, Mengin-Lecreulx D, van Heijenoort J, Arthur M. 2002. Synthesis of the L -alanyl-L-alanine cross-bridge of Enterococcus faecalis peptidoglycan. J Biol Chem 277:45935-45941. http://dx.doi.org/10.1074/jbc.M2074 49200.
69. Staroske T, Williams DH. 1998. Synthesis of covalent head-to-tail dimers of vancomycin. Tetrahedron Lett 39:4917-4920. http://dx.doi.org/10 .1016/S0040-4039(98)00895-8.
70. Kim SJ, Singh M, Schaefer J. 2009. Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus. J Mol Biol 391:414-425. http://dx.doi.org/10.1016/j.jmb.2009.06.033.
71. Chilton CH, Freeman J, Baines SD, Crowther S, Nicholson S, Wilcox MH. 2013. Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. J Antimicrob Chemother 68:2078-2082. http://dx.doi.org/10.1093/jac/dkt160.